BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hanai H, Watanabe F, Saniabadi AR, Matsushitai I, Takeuchi K, Iida T. Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 2002;47:2349-53. [PMID: 12395908 DOI: 10.1023/a:1020159932758] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Chen XL, Mao JW, Wang YD. Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future. World J Gastrointest Pathophysiol 2020; 11(3): 43-56 [PMID: 32435521 DOI: 10.4291/wjgp.v11.i3.43] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
2 Iida T, Ikeya K, Kato M, Abe J, Yamamoto M, Watanabe F, Sugimoto K, Hanai H. Adsorptive Depletion of Myeloid Lineage Leucocytes as Remission Induction Therapy in Patients with Ulcerative Colitis after Failure of First-Line Medications: Results from a Three-Year Real World, Clinical Practice. Digestion 2017;96:119-26. [PMID: 28796990 DOI: 10.1159/000479502] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
3 Rolandsdotter H, Jönsson-Videsäter K, L Fagerberg U, Eberhardson M, Finkel Y. Mucosal Cytokine Profiles After Induction Therapy With Granulocyte/Monocyte Apheresis in New-onset Inflammatory Colitis. J Pediatr Gastroenterol Nutr 2018;66:e103-7. [PMID: 28891831 DOI: 10.1097/MPG.0000000000001735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Rolandsdotter H, Eberhardson M, Fagerberg UL, Finkel Y. Granulocyte and Monocyte Apheresis for Induction of Remission in Children With New-Onset Inflammatory Bowel Colitis. J Pediatr Gastroenterol Nutr 2018;66:84-9. [PMID: 28604509 DOI: 10.1097/MPG.0000000000001641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Kanai T. Leukocytapheresis Therapy of Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_49] [Reference Citation Analysis]
6 Ghosh S, Iacucci M. Acute severe ulcerative colitis. Gastrointestinal emergencies 2016. [DOI: 10.1002/9781118662915.ch34] [Reference Citation Analysis]
7 Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
8 Nakano R, Iwakiri R, Ikeda Y, Kishi T, Tsuruoka N, Shimoda R, Sakata Y, Yamaguchi K, Fujimoto K. Factors affecting short- and long-term effects of leukocyte removal therapy in active ulcerative colitis. J Gastroenterol Hepatol 2013;28:303-8. [PMID: 23339387 DOI: 10.1111/jgh.12049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
9 Aherne CM, Collins CB, Masterson JC, Tizzano M, Boyle TA, Westrich JA, Parnes JA, Furuta GT, Rivera-Nieves J, Eltzschig HK. Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis. Gut 2012;61:695-705. [PMID: 21813473 DOI: 10.1136/gutjnl-2011-300012] [Cited by in Crossref: 91] [Cited by in F6Publishing: 98] [Article Influence: 8.3] [Reference Citation Analysis]
10 Nakase H, Uza N, Matsuura M, Chiba T. Importance of CXCL16 as a biomarker for granulocytapheresis in patients with Crohn's disease. Inflamm Bowel Dis 2011;17:2211-2. [PMID: 21391290 DOI: 10.1002/ibd.21657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
11 Fujisawa T, Murase K, Okumura Y, Kanoh H, Doi T, Yoshida S, Ogura S, Seishima M. Generalized pustular psoriasis successfully treated with granulocyte and monocyte adsorption apheresis. Ther Apher Dial 2011;15:374-8. [PMID: 21884472 DOI: 10.1111/j.1744-9987.2011.00961.x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Habermalz B, Sauerland S. Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis. Dig Dis Sci 2010;55:1421-8. [PMID: 19517236 DOI: 10.1007/s10620-009-0845-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
13 Helmy A, Abdulla M, Kagevi I, Al Kahtani K. Leukocyte apheresis in the management of ulcerative colitis. Saudi J Gastroenterol 2009;15:283-7. [PMID: 19794281 DOI: 10.4103/1319-3767.56093] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Hanai H. Leucocytapheresis for inflammatory bowel disease in the era of biologic therapy. Eur J Gastroenterol Hepatol 2008;20:596-600. [PMID: 18679059 DOI: 10.1097/MEG.0b013e3282f5e9f3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
15 Munoz J. Therapeutic Apheresis procedures: mechanisms of action and Immunomodulatory effects. ISBT Science Series 2008;3:95-103. [DOI: 10.1111/j.1751-2824.2008.00178.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kageoka M, Ikeya K, Yamada M, Kikuyama M, Iwaoka Y, Hirayama K, Nagata S, Sato Y, Hosoda Y. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis 2008;40:433-40. [PMID: 18296130 DOI: 10.1016/j.dld.2008.01.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
17 Martín de Carpi J, Vilar P, Prieto G, García Novo MD, Ribes C, Varea V. Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study. J Pediatr Gastroenterol Nutr 2008;46:386-91. [PMID: 18367949 DOI: 10.1097/MPG.0b013e31815604e5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
18 Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol 2007;102:2058-69. [PMID: 17561966 DOI: 10.1111/j.1572-0241.2007.01343.x] [Cited by in Crossref: 158] [Cited by in F6Publishing: 162] [Article Influence: 9.9] [Reference Citation Analysis]
19 Muñoz J, Clavo M, Garcia O, Reina D, Vidaller A, Lafuente R, Massuet LI. Adsorptive monocyte and granulocyte apheresis in the chronic inflammatory illness: ulcerous colitis, Crohn's disease, rheumatoid arthritis and Behcet syndrome. ISBT Science Series 2007;2:96-101. [DOI: 10.1111/j.1751-2824.2007.00067.x] [Reference Citation Analysis]
20 Panés J, Guilera M, Ginard D, Hinojosa J, González-Carro P, González-Lara V, Varea V, Domènech E, Badia X. Treatment cost of ulcerative colitis is apheresis with Adacolumn cost-effective? Dig Liver Dis 2007;39:617-25. [PMID: 17531555 DOI: 10.1016/j.dld.2007.03.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
21 Aoki H, Nakamura K, Yoshimatsu Y, Tsuda Y, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y. Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes. Dig Dis Sci 2007;52:1427-33. [PMID: 17394078 DOI: 10.1007/s10620-006-9406-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
22 Takemoto K, Kato J, Kuriyama M, Nawa T, Kurome M, Okada H, Sakaguchi K, Shiratori Y. Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients. Dig Liver Dis 2007;39:422-9. [PMID: 17379587 DOI: 10.1016/j.dld.2007.01.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
23 Emmrich J. Leucocytapheresis. Falk Symposium. [DOI: 10.1007/1-4020-4316-3_24] [Reference Citation Analysis]
24 Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577 [PMID: 17171783 DOI: 10.3748/wjg.v12.i47.7568] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
25 Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006;51:2031-8. [PMID: 17004123 DOI: 10.1007/s10620-006-9199-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
26 Ikeda H, Ishimaru Y, Takayasu H, Fujino J, Kisaki Y, Otani Y, Yamagishi J, Tahara K. Efficacy of granulocyte apheresis in pediatric patients with ulcerative colitis: a pilot study. J Pediatr Gastroenterol Nutr 2006;43:592-6. [PMID: 17130733 DOI: 10.1097/01.mpg.0000237928.07729.79] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
27 Ikeuchi H, Yamamura T, Kusunoki M, Nakano H, Uchino M, Nakamura M, Noda M, Yanagi H, Matsumoto T. Leukocyte removal therapy for ulcerative colitis does not affect postoperative complications. J Gastroenterol 2006;41:848-54. [PMID: 17048048 DOI: 10.1007/s00535-006-1875-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
28 Sakimura K, Omori T, Iwashita E, Yoshida T, Tsuzuki Y, Fujimori K, Konishi F, Yoshida Y, Anzai H, Suzuki H, Sugawara S, Takeda Y, Hiraishi K, Saniabadi AR, Ide T, Miura S, Ota S. Clinical response is associated with elevated plasma interleukin-1 receptor antagonist during selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006;51:1525-31. [PMID: 16902810 DOI: 10.1007/s10620-005-9012-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
29 Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, Ost A, Hittel N, Saniabadi A, Löfberg R. Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis 2006;21:493-504. [PMID: 16538495 DOI: 10.1007/s00384-005-0069-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
30 Matsui T. Leukocyte removal therapy before surgery in ulcerative colitis. J Gastroenterol 2006;41:923-4. [PMID: 17048060 DOI: 10.1007/s00535-006-1898-7] [Reference Citation Analysis]
31 Yamamoto T, Saniabadi AR, Umegae S, Matsumoto K. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamm Bowel Dis 2006;12:719-26. [PMID: 16917227 DOI: 10.1097/00054725-200608000-00008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
32 Hanai H, Iida T, Yamada M, Sato Y, Takeuchi K, Tanaka T, Kondo K, Kikuyama M, Maruyama Y, Iwaoka Y, Nakamura A, Hirayama K, Saniabadi AR, Watanabe F. Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis. World J Gastroenterol 2006; 12(21): 3393-3399 [PMID: 16733857 DOI: 10.3748/wjg.v12.i21.3393] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
33 Nishise S, Takeda Y, Takeda H, Ishihama K, Fukui T, Kawata S. Complement activation is involved in biological responses to leukocyte adsorptive apheresis. Dig Dis Sci 2006;51:934-41. [PMID: 16642423 DOI: 10.1007/s10620-005-9050-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
34 Sandborn WJ. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis 2006;12 Suppl 1:S15-21. [PMID: 16378006 DOI: 10.1097/01.mib.0000195387.26892.22] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
35 Yanaru-Fujisawa R, Matsumoto T, Nakamura S, Kochi S, Iida M, Kohda F, Hirahashi M, Yao T, Mibu R. Granulocyte apheresis for pouchitis with arthritis and pyoderma gangrenosum after restorative proctocolectomy for ulcerative colitis: a case report. Inflamm Bowel Dis 2005;11:780-1. [PMID: 16043996 DOI: 10.1097/01.mib.0000172558.39767.b7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
36 Sawada K, Kashiwamura S, Okamura H, Ohnishi K, Fukunaga K, Hirata I, Saniabadi A. Selective granulocyte and monocyte apheresis as a new adjunct to enhance the efficacy of interferon-alpha + ribavirin in patients with high plasma hepatitis C virus. Dig Liver Dis 2005;37:515-21. [PMID: 15975539 DOI: 10.1016/j.dld.2005.01.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
37 Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, Shimoyama T. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005;100:1362-9. [PMID: 15929771 DOI: 10.1111/j.1572-0241.2005.41089.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 5.7] [Reference Citation Analysis]
38 Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kikuyama M, Tanaka T, Kondo K, Tanaka K, Takai K. Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis. World J Gastroenterol 2005; 11(20): 3085-3090 [PMID: 15918195 DOI: 10.3748/wjg.v11.i20.3085] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
39 Sawada K, Masaki N, Hayashi S, Zeniya M, Ishikawa T, Takahashi H, Ohnishi K, Fukunaga K, Hara N, Yamamoto T, Hada T, Toda G. Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-alpha2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia. J Viral Hepat 2005;12:274-82. [PMID: 15850468 DOI: 10.1111/j.1365-2893.2005.00577.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
40 Sawada K, Egashira A, Ohnishi K, Fukunaga K, Kusaka T, Shimoyama T. Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon. Dig Dis Sci 2005;50:767-73. [PMID: 15844716 DOI: 10.1007/s10620-005-2571-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
41 Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis 2004;36:811-7. [PMID: 15646427 DOI: 10.1016/j.dld.2004.08.004] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 3.9] [Reference Citation Analysis]
42 Mori K, Yoshihara T, Ando T, Tsubai S, Matsuo S, Aoyama M, Yamamoto T, Kawase Y. Cytapheresis therapy for ulcerative colitis in three pediatric patients. J Pediatr Gastroenterol Nutr 2004;39:549-51. [PMID: 15572898 DOI: 10.1097/00005176-200411000-00019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
43 Hanai H, Takeuchi K, Iida T, Kashiwagi N, Saniabadi AR, Matsushita I, Sato Y, Kasuga N, Nakamura T. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci 2004;49:1438-43. [PMID: 15481316 DOI: 10.1023/b:ddas.0000042243.47279.87] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 4.5] [Reference Citation Analysis]
44 Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I, Iwaoka Y, Saniabadi A. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol 2004;99:1532-8. [PMID: 15307873 DOI: 10.1111/j.1572-0241.2004.30432.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 3.2] [Reference Citation Analysis]
45 Premehand P, Takeuchi K, Bjarnason I. Selective bloodletting for severe ulcerative colitis. Scand J Gastroenterol 2004;39:416-7. [PMID: 15180176 DOI: 10.1080/00365520410008854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004;49:565-71. [PMID: 15185858 DOI: 10.1023/b:ddas.0000026299.43792.ae] [Cited by in Crossref: 117] [Cited by in F6Publishing: 97] [Article Influence: 6.2] [Reference Citation Analysis]